End-of-day quote
Taiwan S.E.
03:30:00 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
95.4
TWD
|
+0.74%
|
|
-1.24%
|
-14.82%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,408
|
6,584
|
6,530
|
6,448
|
15,347
|
9,603
|
Enterprise Value (EV)
1 |
5,741
|
6,230
|
7,395
|
6,613
|
15,382
|
9,827
|
P/E ratio
|
40.1
x
|
40.9
x
|
236
x
|
57
x
|
84.4
x
|
124
x
|
Yield
|
2.16%
|
2.1%
|
0.82%
|
1.99%
|
1.12%
|
1.34%
|
Capitalization / Revenue
|
4.55
x
|
4.18
x
|
4.16
x
|
3.39
x
|
6.4
x
|
5.1
x
|
EV / Revenue
|
4.08
x
|
3.96
x
|
4.71
x
|
3.48
x
|
6.41
x
|
5.22
x
|
EV / EBITDA
|
22.6
x
|
23
x
|
46.2
x
|
24
x
|
28.2
x
|
33
x
|
EV / FCF
|
65.6
x
|
-145
x
|
-40.3
x
|
35.2
x
|
51.2
x
|
210
x
|
FCF Yield
|
1.53%
|
-0.69%
|
-2.48%
|
2.84%
|
1.95%
|
0.48%
|
Price to Book
|
4.74
x
|
4.84
x
|
5.27
x
|
3.34
x
|
7.65
x
|
5.02
x
|
Nbr of stocks (in thousands)
|
76,739
|
76,739
|
76,739
|
85,739
|
85,739
|
85,739
|
Reference price
2 |
83.50
|
85.80
|
85.10
|
75.20
|
179.0
|
112.0
|
Announcement Date
|
18/03/19
|
26/03/20
|
22/03/21
|
25/03/22
|
31/03/23
|
14/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,409
|
1,574
|
1,569
|
1,901
|
2,399
|
1,882
|
EBITDA
1 |
253.7
|
270.3
|
160.2
|
275.7
|
546.3
|
298.2
|
EBIT
1 |
212.5
|
223.9
|
104.5
|
165.3
|
414
|
156.8
|
Operating Margin
|
15.09%
|
14.23%
|
6.66%
|
8.7%
|
17.26%
|
8.33%
|
Earnings before Tax (EBT)
1 |
244.4
|
226.3
|
89.41
|
182.7
|
333.4
|
168.7
|
Net income
1 |
159.2
|
161.3
|
27.9
|
104.4
|
182.3
|
77.22
|
Net margin
|
11.3%
|
10.25%
|
1.78%
|
5.49%
|
7.6%
|
4.1%
|
EPS
2 |
2.080
|
2.100
|
0.3600
|
1.319
|
2.120
|
0.9000
|
Free Cash Flow
1 |
87.58
|
-43.02
|
-183.4
|
187.8
|
300.7
|
46.79
|
FCF margin
|
6.22%
|
-2.73%
|
-11.69%
|
9.88%
|
12.54%
|
2.49%
|
FCF Conversion (EBITDA)
|
34.52%
|
-
|
-
|
68.11%
|
55.04%
|
15.69%
|
FCF Conversion (Net income)
|
55.02%
|
-
|
-
|
179.88%
|
164.89%
|
60.6%
|
Dividend per Share
2 |
1.800
|
1.800
|
0.7000
|
1.500
|
2.000
|
1.500
|
Announcement Date
|
18/03/19
|
26/03/20
|
22/03/21
|
25/03/22
|
31/03/23
|
14/03/24
|
Fiscal Period: December |
2021 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
529.4
|
-
|
470.1
|
474.6
|
EBITDA
|
-
|
-
|
-
|
-
|
EBIT
1 |
67.13
|
-
|
45.38
|
42.68
|
Operating Margin
|
12.68%
|
-
|
9.65%
|
8.99%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
Net income
|
-
|
22.69
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
EPS
|
-
|
0.2600
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
15/05/23
|
11/08/23
|
14/11/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
864
|
165
|
34.7
|
225
|
Net Cash position
1 |
666
|
354
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
5.394
x
|
0.5997
x
|
0.0635
x
|
0.7529
x
|
Free Cash Flow
1 |
87.6
|
-43
|
-183
|
188
|
301
|
46.8
|
ROE (net income / shareholders' equity)
|
14.6%
|
11.9%
|
2.15%
|
6.58%
|
9.26%
|
3.94%
|
ROA (Net income/ Total Assets)
|
8.62%
|
7.47%
|
2.62%
|
3.43%
|
8.56%
|
3.1%
|
Assets
1 |
1,847
|
2,160
|
1,065
|
3,045
|
2,131
|
2,493
|
Book Value Per Share
2 |
17.60
|
17.70
|
16.20
|
22.50
|
23.40
|
22.30
|
Cash Flow per Share
2 |
7.760
|
4.750
|
4.040
|
3.260
|
5.410
|
6.240
|
Capex
1 |
39.8
|
112
|
101
|
170
|
199
|
181
|
Capex / Sales
|
2.83%
|
7.1%
|
6.45%
|
8.94%
|
8.28%
|
9.63%
|
Announcement Date
|
18/03/19
|
26/03/20
|
22/03/21
|
25/03/22
|
31/03/23
|
14/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -14.82% | 250M | | +30.15% | 682B | | +30.35% | 586B | | -3.75% | 364B | | +17.66% | 327B | | +3.60% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +7.45% | 165B |
Other Pharmaceuticals
|